1. Psychophysiologic Symptom Relief Therapy for Post-Acute Sequelae of Coronavirus Disease 2019
- Author
-
Michael Donnino, MD, Patricia Howard, BS, Shivani Mehta, BA, Jeremy Silverman, BA, Maria J. Cabrera, BA, Jolin B. Yamin, PhD, Lakshman Balaji, MPH, Katherine M. Berg, MD, Stanley Heydrick, PhD, Robert Edwards, PhD, and Anne V. Grossestreuer, PhD, MSc
- Subjects
Medicine (General) ,R5-920 - Abstract
Objective: To determine if psychophysiologic symptom relief therapy (PSRT) will reduce symptom burden in patients suffering from post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC) who had mild/moderate acute COVID-19 disease without objective evidence of organ injury. Patients and Methods: Twenty-three adults under the age of 60 years with PASC for at least 12 weeks after COVID-19 infection were enrolled in an interventional cohort study conducted via a virtual platform between May 18, 2021 and August 7, 2022. Participants received PSRT during a 13-week (approximately 44-hour) course. Participants were administered validated questionnaires at baseline and at 4, 8, and 13 weeks. The primary outcome was a change in somatic symptoms from baseline, measured using the Somatic Symptom Scale-8, at 13 weeks. Results: The median duration of symptoms before joining the study was 267 days (interquartile range: 144, 460). The mean Somatic Symptom Scale-8 score of the cohort decreased from baseline by 8.5 (95% CI: 5.7-11.4), 9.4 (95% CI: 6.9-11.9), and 10.9 (95% CI: 8.3-13.5) at 4, 8, and 13 weeks, respectively (all P
- Published
- 2023
- Full Text
- View/download PDF